Physician profile

Christopher Murray

Internal Medicine · Beaver Falls, PA

NPI 1760833974

$666.17

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$68.91

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $307.22 2020-2023 Rybelsus, Ozempic
Janssen Scientific Affairs, LLC $123.98 2019
Abbvie INC. $48.16 2021-2022
Esperion Therapeutics, INC. $34.13 2021-2023 Nexletol
Lilly USA, LLC $26.70 2020-2022
Amgen INC. $26.24 2022-2023 Repatha
Janssen Pharmaceuticals, INC $19.16 2020
Boehringer Ingelheim Pharmaceuticals, INC. $17.38 2022
Novartis Pharmaceuticals Corporation $15.46 2020
Glaxosmithkline, LLC. $14.94 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Christopher Murray

$666.17

in general payments reported 2019-2025

Years
2019-2023
Top company
Novo Nordisk INC

https://glasscript.com/doctor/1474675/christopher-murray

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.